Early intervention can be facilitated by combining inflammatory indicators such as IL-6 with ferritin, Lactate Dehydrogenase, Procalcitonin, Neutrophils, neutrophil/lymphocyte ratio (NLR), Lactate Dehydrogenase/ Lymphocyte Ratio and CRP on admission levels, since this can enhance estimating the COVID-19 patients' severity.There have been several studies undertaken on the condition,including biomarkers for diagnosis, prognosis, prevention strategies and prospective treatmen. In this study, a comprehensive analysis of data from non-severe and severe confirmed Patients with COVID-19 revealed that males were more significantly affected by the severe disease, and diabetes mellitus was also significantly linked to the severity of the disease. Furthermore, the most prevalent presenting symptoms during the hospital admission were cough, dyspnea, and fever. According to the current study's findings, individuals with severe COVID-19 consumed considerably elevated grades of inflammation and coagulation indicators (ferritin, CRP, neutrophils, and D dimer) than those with mild COVID-19. This study was directed in patients who confirmed COVID-19. The study also examined the possible suggestions of targeting these inflammatory biomarkers to improve treatment effectiveness and minimize negative side effects. This study was conducted to evaluate if combining baseline inflammatory biomarkers could improve COVID-19 severity prediction. This study targeted to see whether integrating baseline inflammatory indicators and the NLR and LDH/L ratio could enhance the forecast of COVID-19 severity and are reliable predictors of outcomes.They might be applied as a quick, dependable tool for COVID-19 patient care that is done efficiently.Conclusion:The purpose of this study is to see whether integrating inflammatory indicators could enhance the forecast of COVID-19 Severity